Pub Date : 2025-01-10DOI: 10.1176/appi.neuropsych.20240150
Clare M Eglin, Heather Massey, Michael J Tipton
{"title":"A Jump Into Cold Water or a Leap of Faith?","authors":"Clare M Eglin, Heather Massey, Michael J Tipton","doi":"10.1176/appi.neuropsych.20240150","DOIUrl":"https://doi.org/10.1176/appi.neuropsych.20240150","url":null,"abstract":"","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":" ","pages":"appineuropsych20240150"},"PeriodicalIF":2.4,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1176/appi.neuropsych.20240099
Cameron A Ryczek, Rhiannon Rivas, Lea Hemphill, Zackary Zanotelli, Nicholas Renteria, Khashayar Dashtipour, Jacob D Jones
Objective: Cognitive impairment is a common nonmotor symptom among individuals with Parkinson's disease (PD). Although cognitive impairment generally develops progressively, individuals with PD-associated mild cognitive impairment (PD-MCI) may revert to being cognitively normal (CN), which is referred to as PD-MCI reversion. Previous studies are inconsistent in whether PD-MCI reverters are at greater risk for PD-MCI recurrence relative to CN individuals. Even less is known about how PD-MCI reverters compare with CN individuals or PD-MCI nonreverters in terms of neurodegenerative biomarkers. The authors examined group differences (CN, PD-MCI reversion, and PD-MCI nonreversion) in cerebrospinal fluid (CSF) markers of Alzheimer's disease (AD), including amyloid beta, tau (total [t-tau] and phosphorylated [p-tau]), and alpha-synuclein.
Methods: Data from the longitudinal international multisite Parkinson Progression Marker Initiative were used. Participants were newly diagnosed as having PD (N=430) and completed a battery of neurocognitive assessments at baseline and annual follow-ups for up to 5 years. Participants were classified as CN, PD-MCI reverters, or PD-MCI nonreverters on the basis of the first two neurocognitive assessments.
Results: The PD-MCI nonreversion group had greater p-tau:amyloid beta and t-tau:amyloid beta ratios relative to the PD-MCI reversion group. The CN and PD-MCI reversion groups did not significantly differ in any of the CSF markers.
Conclusions: PD-MCI reverters may have a more favorable trajectory in terms of AD pathology relative to PD-MCI nonreverters. Future studies are needed to verify whether PD-MCI reversion may represent an intermediate prognostic group between CN individuals and those with MCI nonreversion.
{"title":"Association of Favorable Cerebrospinal Fluid Markers With Reversion of Mild Cognitive Impairment Due to Parkinson's Disease.","authors":"Cameron A Ryczek, Rhiannon Rivas, Lea Hemphill, Zackary Zanotelli, Nicholas Renteria, Khashayar Dashtipour, Jacob D Jones","doi":"10.1176/appi.neuropsych.20240099","DOIUrl":"https://doi.org/10.1176/appi.neuropsych.20240099","url":null,"abstract":"<p><strong>Objective: </strong>Cognitive impairment is a common nonmotor symptom among individuals with Parkinson's disease (PD). Although cognitive impairment generally develops progressively, individuals with PD-associated mild cognitive impairment (PD-MCI) may revert to being cognitively normal (CN), which is referred to as PD-MCI reversion. Previous studies are inconsistent in whether PD-MCI reverters are at greater risk for PD-MCI recurrence relative to CN individuals. Even less is known about how PD-MCI reverters compare with CN individuals or PD-MCI nonreverters in terms of neurodegenerative biomarkers. The authors examined group differences (CN, PD-MCI reversion, and PD-MCI nonreversion) in cerebrospinal fluid (CSF) markers of Alzheimer's disease (AD), including amyloid beta, tau (total [t-tau] and phosphorylated [p-tau]), and alpha-synuclein.</p><p><strong>Methods: </strong>Data from the longitudinal international multisite Parkinson Progression Marker Initiative were used. Participants were newly diagnosed as having PD (N=430) and completed a battery of neurocognitive assessments at baseline and annual follow-ups for up to 5 years. Participants were classified as CN, PD-MCI reverters, or PD-MCI nonreverters on the basis of the first two neurocognitive assessments.</p><p><strong>Results: </strong>The PD-MCI nonreversion group had greater p-tau:amyloid beta and t-tau:amyloid beta ratios relative to the PD-MCI reversion group. The CN and PD-MCI reversion groups did not significantly differ in any of the CSF markers.</p><p><strong>Conclusions: </strong>PD-MCI reverters may have a more favorable trajectory in terms of AD pathology relative to PD-MCI nonreverters. Future studies are needed to verify whether PD-MCI reversion may represent an intermediate prognostic group between CN individuals and those with MCI nonreversion.</p>","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":" ","pages":"appineuropsych20240099"},"PeriodicalIF":2.4,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1176/appi.neuropsych.20240020
Yu-Lien Huang, Tzu-Ting Chen, Wei-Shin Wang, Che Yu Kuo, Yen Kuang Yang, Huai-Hsuan Tseng
Objective: Social cognition is defined as the ability to construct mental representations about oneself, others, and one's relationships with others to guide social behaviors, including referring to mental states (cognitive factor) and understanding emotional states (affective factor). Difficulties in social cognition may be symptoms of schizophrenia. The authors examined associations between two factors of social cognition and specific schizophrenia symptoms, as well as a potential path from low-level affective perceptual social cognition to high-level social cognition, which may be associated with schizophrenia symptoms.
Methods: The authors compared IQ, executive function, and social cognition scores of 41 patients with schizophrenia with those of a community-based group of 30 healthy individuals by using the Diagnostic Analysis of Nonverbal Accuracy 2-Taiwan version, the Movie for the Assessment of Social Cognition-Taiwan version, and the Chinese version of the theory of mind task.
Results: In analyses controlled for IQ and executive function scores, patients with schizophrenia were found to perform more poorly than individuals in the healthy comparison group on all social cognition tasks. Disorganized symptoms were associated with lower accuracy of recognizing happy and angry faces, a lower verbal theory of mind score, and altered low- and high-level social cognition scores. A potential causal link was identified between low-level affective perceptual social cognition and high-level social cognition, resulting in disorganized symptoms.
Conclusions: These results indicate distinct roles of two factors of social cognition in schizophrenia symptomatology and provide a new direction for alleviating symptoms of this disorder by enhancing social cognition.
{"title":"Low Versus High Levels of Social Cognition Impairment and Their Associations With Specific Schizophrenia Symptom Domains.","authors":"Yu-Lien Huang, Tzu-Ting Chen, Wei-Shin Wang, Che Yu Kuo, Yen Kuang Yang, Huai-Hsuan Tseng","doi":"10.1176/appi.neuropsych.20240020","DOIUrl":"https://doi.org/10.1176/appi.neuropsych.20240020","url":null,"abstract":"<p><strong>Objective: </strong>Social cognition is defined as the ability to construct mental representations about oneself, others, and one's relationships with others to guide social behaviors, including referring to mental states (cognitive factor) and understanding emotional states (affective factor). Difficulties in social cognition may be symptoms of schizophrenia. The authors examined associations between two factors of social cognition and specific schizophrenia symptoms, as well as a potential path from low-level affective perceptual social cognition to high-level social cognition, which may be associated with schizophrenia symptoms.</p><p><strong>Methods: </strong>The authors compared IQ, executive function, and social cognition scores of 41 patients with schizophrenia with those of a community-based group of 30 healthy individuals by using the Diagnostic Analysis of Nonverbal Accuracy 2-Taiwan version, the Movie for the Assessment of Social Cognition-Taiwan version, and the Chinese version of the theory of mind task.</p><p><strong>Results: </strong>In analyses controlled for IQ and executive function scores, patients with schizophrenia were found to perform more poorly than individuals in the healthy comparison group on all social cognition tasks. Disorganized symptoms were associated with lower accuracy of recognizing happy and angry faces, a lower verbal theory of mind score, and altered low- and high-level social cognition scores. A potential causal link was identified between low-level affective perceptual social cognition and high-level social cognition, resulting in disorganized symptoms.</p><p><strong>Conclusions: </strong>These results indicate distinct roles of two factors of social cognition in schizophrenia symptomatology and provide a new direction for alleviating symptoms of this disorder by enhancing social cognition.</p>","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":" ","pages":"appineuropsych20240020"},"PeriodicalIF":2.4,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-07-11DOI: 10.1176/appi.neuropsych.20230205
Molly K Wiggins, Emily P Pharr, Jennifer L Wood, Suzanne Craft, William T Harrison, James R Bateman
{"title":"Dementia With Lewy Bodies Phenocopy in a Case of RT-QuIC-Negative Creutzfeldt-Jakob Disease: Implications of Functional Anatomy.","authors":"Molly K Wiggins, Emily P Pharr, Jennifer L Wood, Suzanne Craft, William T Harrison, James R Bateman","doi":"10.1176/appi.neuropsych.20230205","DOIUrl":"10.1176/appi.neuropsych.20230205","url":null,"abstract":"","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":" ","pages":"93-96"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1176/appi.neuropsych.20240173
Wilfredo López-Ojeda, Robin A Hurley
{"title":"Myokines and the Brain: A Novel Neuromuscular Endocrine Loop.","authors":"Wilfredo López-Ojeda, Robin A Hurley","doi":"10.1176/appi.neuropsych.20240173","DOIUrl":"https://doi.org/10.1176/appi.neuropsych.20240173","url":null,"abstract":"","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":"37 1","pages":"A4-4"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1176/appi.neuropsych.20240221
David B Arciniegas
{"title":"A Note of Gratitude to C. Alan Anderson, M.D., Deputy Editor, <i>Journal of Neuropsychiatry and Clinical Neurosciences</i>.","authors":"David B Arciniegas","doi":"10.1176/appi.neuropsych.20240221","DOIUrl":"https://doi.org/10.1176/appi.neuropsych.20240221","url":null,"abstract":"","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":"37 1","pages":"5"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-07-22DOI: 10.1176/appi.neuropsych.20230231
Mark Ainsley Colijn
Psychotic symptoms frequently occur in idiopathic Parkinson's disease (PD) and often require treatment with antipsychotic therapy. Most antipsychotics have the potential to worsen the motor symptoms of PD; quetiapine, clozapine, and pimavanserin are commonly used for the treatment of idiopathic PD because these medications tend to be comparatively well tolerated. Although psychotic symptoms may also occur in monogenic forms of PD, no reviews have focused on the use of antipsychotic medications in this context. The objective of the present systematic review was to characterize the effectiveness and tolerability of quetiapine, clozapine, and pimavanserin in monogenic PD-associated psychosis. A literature search was performed with PubMed, Scopus, and Embase. The search yielded 24 eligible articles describing 30 individuals, although treatment response with respect to psychotic symptoms was described in only 11 cases; of these, six individuals experienced symptomatic improvement or remission (four with clozapine and two with quetiapine), two exhibited a poor therapeutic response (one to clozapine and one to quetiapine), and the other three responded initially to antipsychotic therapy before experiencing a recurrence of symptoms. The use of quetiapine and clozapine in GBA variant-associated PD is briefly reviewed separately. Notably, no reports of pimavanserin therapy were identified. In keeping with the idiopathic PD literature, relatively low doses of medication were used in most cases. Lastly, side effects were rarely reported. Although quetiapine and particularly clozapine may be effective and well tolerated in the treatment of monogenic PD psychosis, this review highlights the paucity of available evidence to guide clinical decision making in this context.
特发性帕金森病(PD)经常出现精神症状,通常需要使用抗精神病药物治疗。大多数抗精神病药物都有可能加重帕金森病的运动症状;喹硫平、氯氮平和皮马伐林常用于治疗特发性帕金森病,因为这些药物的耐受性相对较好。虽然单基因型帕金森病也可能出现精神病性症状,但还没有综述关注抗精神病药物在这种情况下的使用。本系统性综述旨在描述喹硫平、氯氮平和皮马凡瑟林对单基因帕金森病相关精神病的有效性和耐受性。我们在 PubMed、Scopus 和 Embase 上进行了文献检索。检索结果显示,有24篇符合条件的文章描述了30名患者的情况,但只有11个病例描述了精神病症状的治疗反应;其中,6名患者的症状得到改善或缓解(4名患者使用氯氮平,2名患者使用喹硫平),2名患者的治疗反应不佳(1名患者使用氯氮平,1名患者使用喹硫平),另外3名患者最初对抗精神病治疗有反应,但随后症状复发。本文将单独简要回顾喹硫平与氯氮平在 GBA 变异相关型帕金森病中的应用。值得注意的是,没有发现关于匹马塞林治疗的报道。与特发性帕金森病的文献一致,大多数病例使用的药物剂量相对较小。最后,很少有副作用的报道。尽管喹硫平,尤其是氯氮平在治疗单基因帕金森氏症精神病方面可能有效且耐受性良好,但本综述强调了在这种情况下指导临床决策的可用证据的匮乏。
{"title":"Quetiapine, Clozapine, and Pimavanserin Treatment Response in Monogenic Parkinson's Disease Psychosis: A Systematic Review.","authors":"Mark Ainsley Colijn","doi":"10.1176/appi.neuropsych.20230231","DOIUrl":"10.1176/appi.neuropsych.20230231","url":null,"abstract":"<p><p>Psychotic symptoms frequently occur in idiopathic Parkinson's disease (PD) and often require treatment with antipsychotic therapy. Most antipsychotics have the potential to worsen the motor symptoms of PD; quetiapine, clozapine, and pimavanserin are commonly used for the treatment of idiopathic PD because these medications tend to be comparatively well tolerated. Although psychotic symptoms may also occur in monogenic forms of PD, no reviews have focused on the use of antipsychotic medications in this context. The objective of the present systematic review was to characterize the effectiveness and tolerability of quetiapine, clozapine, and pimavanserin in monogenic PD-associated psychosis. A literature search was performed with PubMed, Scopus, and Embase. The search yielded 24 eligible articles describing 30 individuals, although treatment response with respect to psychotic symptoms was described in only 11 cases; of these, six individuals experienced symptomatic improvement or remission (four with clozapine and two with quetiapine), two exhibited a poor therapeutic response (one to clozapine and one to quetiapine), and the other three responded initially to antipsychotic therapy before experiencing a recurrence of symptoms. The use of quetiapine and clozapine in <i>GBA</i> variant-associated PD is briefly reviewed separately. Notably, no reports of pimavanserin therapy were identified. In keeping with the idiopathic PD literature, relatively low doses of medication were used in most cases. Lastly, side effects were rarely reported. Although quetiapine and particularly clozapine may be effective and well tolerated in the treatment of monogenic PD psychosis, this review highlights the paucity of available evidence to guide clinical decision making in this context.</p>","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":" ","pages":"6-13"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-10-10DOI: 10.1176/appi.neuropsych.20240016
Antonio Bulbena-Vilarrasa, Maria Martínez-García, Luis Pintor Pérez, Mercé Camara, Néstor Arbelo-Cabrera, Andrea Bulbena-Cabré, Victor Pérez-Sola, Carolina Baeza-Velasco
Objective: Functional neurological disorder (FND) is a core neuropsychiatric condition that includes both physical and mental symptoms. Recently, a validated clinical phenotype termed neuroconnective endophenotype (NEP), which includes several physical and psychological characteristics together with joint hypermobility (hypermobility spectrum disorders), was found at a significantly higher frequency among patients with anxiety. The purpose of the present study was to examine the presence of the NEP among patients with FND.
Methods: The authors conducted a multicenter case-control study comprising 27 FND patients and 27 healthy control participants (matched by sex and age) ages 13 to 58 years. Eight questionnaires were administered. Proportional differences were examined with Student's t tests, one-way analyses of variance, and chi-square tests.
Results: Differences between FND patients and control participants were observed. FND patients had higher sensory sensitivity, increased prevalence of hypermobility features (including relevant physical signs and symptoms), greater frequency of polarized behaviors, a greater number of both psychiatric and physical comorbidities, and an increase in the characteristics and sensations typical of anxiety. Particularly striking was the presence of the hypermobility spectrum in more than 75% of FND patients compared with 15% among control participants.
Conclusions: FND patients presented higher scores in all five dimensions included in the NEP. Thus, this phenotype, solidifying the original association between anxiety and the hypermobility spectrum, could help to identify an FND subtype when evaluating and managing FND patients, because it provides a new global view of patients' physical and mental symptoms.
{"title":"The Neuroconnective Endophenotype, a New Approach Toward Typing Functional Neurological Disorder: A Case-Control Study.","authors":"Antonio Bulbena-Vilarrasa, Maria Martínez-García, Luis Pintor Pérez, Mercé Camara, Néstor Arbelo-Cabrera, Andrea Bulbena-Cabré, Victor Pérez-Sola, Carolina Baeza-Velasco","doi":"10.1176/appi.neuropsych.20240016","DOIUrl":"10.1176/appi.neuropsych.20240016","url":null,"abstract":"<p><strong>Objective: </strong>Functional neurological disorder (FND) is a core neuropsychiatric condition that includes both physical and mental symptoms. Recently, a validated clinical phenotype termed neuroconnective endophenotype (NEP), which includes several physical and psychological characteristics together with joint hypermobility (hypermobility spectrum disorders), was found at a significantly higher frequency among patients with anxiety. The purpose of the present study was to examine the presence of the NEP among patients with FND.</p><p><strong>Methods: </strong>The authors conducted a multicenter case-control study comprising 27 FND patients and 27 healthy control participants (matched by sex and age) ages 13 to 58 years. Eight questionnaires were administered. Proportional differences were examined with Student's t tests, one-way analyses of variance, and chi-square tests.</p><p><strong>Results: </strong>Differences between FND patients and control participants were observed. FND patients had higher sensory sensitivity, increased prevalence of hypermobility features (including relevant physical signs and symptoms), greater frequency of polarized behaviors, a greater number of both psychiatric and physical comorbidities, and an increase in the characteristics and sensations typical of anxiety. Particularly striking was the presence of the hypermobility spectrum in more than 75% of FND patients compared with 15% among control participants.</p><p><strong>Conclusions: </strong>FND patients presented higher scores in all five dimensions included in the NEP. Thus, this phenotype, solidifying the original association between anxiety and the hypermobility spectrum, could help to identify an FND subtype when evaluating and managing FND patients, because it provides a new global view of patients' physical and mental symptoms.</p>","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":" ","pages":"53-60"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-08-08DOI: 10.1176/appi.neuropsych.20240006
Yenny Valenzuela, Kenya Luna, Ruth Uribe-Kirby, Alejandra Pawlak, Lauren Pitman, Priscilla Cuellar-Rocha, Guadalupe Romero Lucatero, Maria M Santos, Jacob D Jones
Objective: Cognitive impairment is a common nonmotor symptom in Parkinson's disease (PD). Individuals of Latino background are traditionally underrepresented in research on PD. Despite the fact that Latinos comprise 18% of the U.S. population, they commonly make up less than 5% of samples in studies of PD. Emerging evidence suggests that Latino individuals with PD may experience disparities relative to White non-Latinos in terms of having more severe motor symptoms, more severe depressive symptoms, and worse health-related quality of life. The purpose of the present study was to investigate differences in cognitive performance between Latino and White non-Latino individuals with PD and examine correlates of cognitive performance.
Methods: Data were obtained from the Parkinson's Progression Markers Initiative. Participants included 60 Latino individuals with PD and 1,009 White non-Latino individuals with PD, all of whom were followed annually for up to 5 years. Participants completed neuropsychological tests of attention and working memory, processing speed, visuospatial functioning, verbal fluency, and immediate and delayed memory and recall.
Results: Relative to White non-Latino individuals with PD, Latino individuals with PD had significantly lower scores on the global measure of cognitive functioning, a test of processing speed, and tests of working memory and attention. Years of education was the strongest correlate of performance in these three cognitive domains among individuals in the Latino group.
Conclusions: These findings provide initial evidence of disparities in cognitive functioning among Latino individuals with PD. Educational disadvantages may be one potential driver of these disparities.
{"title":"Cognitive Performance of Latino and White Non-Latino Individuals With Parkinson's Disease.","authors":"Yenny Valenzuela, Kenya Luna, Ruth Uribe-Kirby, Alejandra Pawlak, Lauren Pitman, Priscilla Cuellar-Rocha, Guadalupe Romero Lucatero, Maria M Santos, Jacob D Jones","doi":"10.1176/appi.neuropsych.20240006","DOIUrl":"10.1176/appi.neuropsych.20240006","url":null,"abstract":"<p><strong>Objective: </strong>Cognitive impairment is a common nonmotor symptom in Parkinson's disease (PD). Individuals of Latino background are traditionally underrepresented in research on PD. Despite the fact that Latinos comprise 18% of the U.S. population, they commonly make up less than 5% of samples in studies of PD. Emerging evidence suggests that Latino individuals with PD may experience disparities relative to White non-Latinos in terms of having more severe motor symptoms, more severe depressive symptoms, and worse health-related quality of life. The purpose of the present study was to investigate differences in cognitive performance between Latino and White non-Latino individuals with PD and examine correlates of cognitive performance.</p><p><strong>Methods: </strong>Data were obtained from the Parkinson's Progression Markers Initiative. Participants included 60 Latino individuals with PD and 1,009 White non-Latino individuals with PD, all of whom were followed annually for up to 5 years. Participants completed neuropsychological tests of attention and working memory, processing speed, visuospatial functioning, verbal fluency, and immediate and delayed memory and recall.</p><p><strong>Results: </strong>Relative to White non-Latino individuals with PD, Latino individuals with PD had significantly lower scores on the global measure of cognitive functioning, a test of processing speed, and tests of working memory and attention. Years of education was the strongest correlate of performance in these three cognitive domains among individuals in the Latino group.</p><p><strong>Conclusions: </strong>These findings provide initial evidence of disparities in cognitive functioning among Latino individuals with PD. Educational disadvantages may be one potential driver of these disparities.</p>","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":" ","pages":"14-19"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-07-11DOI: 10.1176/appi.neuropsych.20230167
Ayu Imai, Teruyuki Matsuoka, Daisuke Ueno, Jin Narumoto
Objective: Loneliness reportedly increases the risk of dementia, especially Alzheimer's disease (AD). The authors' previous study demonstrated associations between loneliness and structural abnormalities observed in early-stage AD. The present study examined associations between the brain's functional characteristics and loneliness among older adults with concerns about cognitive decline.
Methods: This single-center study included 43 participants (13 with amnestic mild cognitive impairment and 30 with normal cognition). Participants were assessed with the revised University of California Los Angeles (UCLA) Loneliness Scale and underwent resting-state functional MRI. Functional images were preprocessed with the CONN toolbox. The selected seeds were within brain regions reportedly associated with loneliness. One-sample general linear model analysis was performed to examine regressions of UCLA Loneliness Scale scores and functional connectivity between the seeds and regions of interest.
Results: The revised UCLA Loneliness Scale scores were positively correlated with functional connectivity between the right hippocampus and left lateral parietal lobe and were negatively correlated with functional connectivity between the left amygdala and left frontal operculum and between the left amygdala and right supramarginal gyrus. Analyses were adjusted for age, sex, and education and scores on the Mini-Mental State Examination and Clinical Dementia Rating scale.
Conclusions: Loneliness was associated with abnormal function of the hippocampus, parts of the parietal lobe and frontal cortex, and the amygdala. These findings may suggest a possible correlation between loneliness and neurological changes associated with dementia.
{"title":"Loneliness and Resting-State Functional Brain Connectivity Among Older Adults: A Proportional Correlation.","authors":"Ayu Imai, Teruyuki Matsuoka, Daisuke Ueno, Jin Narumoto","doi":"10.1176/appi.neuropsych.20230167","DOIUrl":"10.1176/appi.neuropsych.20230167","url":null,"abstract":"<p><strong>Objective: </strong>Loneliness reportedly increases the risk of dementia, especially Alzheimer's disease (AD). The authors' previous study demonstrated associations between loneliness and structural abnormalities observed in early-stage AD. The present study examined associations between the brain's functional characteristics and loneliness among older adults with concerns about cognitive decline.</p><p><strong>Methods: </strong>This single-center study included 43 participants (13 with amnestic mild cognitive impairment and 30 with normal cognition). Participants were assessed with the revised University of California Los Angeles (UCLA) Loneliness Scale and underwent resting-state functional MRI. Functional images were preprocessed with the CONN toolbox. The selected seeds were within brain regions reportedly associated with loneliness. One-sample general linear model analysis was performed to examine regressions of UCLA Loneliness Scale scores and functional connectivity between the seeds and regions of interest.</p><p><strong>Results: </strong>The revised UCLA Loneliness Scale scores were positively correlated with functional connectivity between the right hippocampus and left lateral parietal lobe and were negatively correlated with functional connectivity between the left amygdala and left frontal operculum and between the left amygdala and right supramarginal gyrus. Analyses were adjusted for age, sex, and education and scores on the Mini-Mental State Examination and Clinical Dementia Rating scale.</p><p><strong>Conclusions: </strong>Loneliness was associated with abnormal function of the hippocampus, parts of the parietal lobe and frontal cortex, and the amygdala. These findings may suggest a possible correlation between loneliness and neurological changes associated with dementia.</p>","PeriodicalId":16559,"journal":{"name":"Journal of Neuropsychiatry and Clinical Neurosciences","volume":" ","pages":"88-92"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}